<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="[4]. A follow-up clinical trial to test efficacy demonstrated that" exact="sofosbuvir" post="was unable to cure any patients with chronic HEV"/>
 <result pre="infection [5]. Recent in silico molecular docking has indicated that" exact="sofosbuvir" post="may inhibit RdRp of SARS-CoV-2 [6]. Without further extensive"/>
 <result pre="inhibit RdRp of SARS-CoV-2 [6]. Without further extensive preclinical studies," exact="sofosbuvir" post="has already entered clinical trials for treating COVID-19 [1]."/>
 <result pre="remdesivir, lopinavir/ritonavir, favipiravir, or interferon alpha, and the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine [1]. Given that many studies have small"/>
 <result pre="favipiravir, or interferon alpha, and the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="[1]. Given that many studies have small patient sizes"/>
 <result pre="this approach can also be applicable to the trials comparing" exact="hydroxychloroquine" post="with standard treatment (Clinical Trial Number: NCT04315948, NCT04261517, and"/>
 <result pre="the management of the COVID-19 pandemicTrends Pharmacol. Sci.41202036338232291112 2.WangM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="for hepatitis E virus?Lancet Gastroenterol. Hepatol.22017154155 5.CornbergM.Efficacy and safety of" exact="sofosbuvir" post="monotherapy in patients with chronic hepatitis E-The HepNet SofE"/>
</results>
